Mar 29, 2010 7:30am EDT Rigel Announces Expiry of Waiting Period Under Hart-Scott-Rodino Act for Licensing Agreement With Astrazeneca
Feb 16, 2010 2:01am EST Rigel to Host Conference Call Today to Discuss Its Partnership With AstraZeneca on Fostamatinib Disodium (R788)
Feb 16, 2010 2:00am EST AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA)
